drugset / Trial / NCT00284271

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

NCT00284271

Phase 2 Completed 65 enrolled University of Cologne
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Timeline

Start
2004-01
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adramycin Unknown
Subject Bleomycin Unknown
Subject Cyclophosphamide Other / unclassified
Subject Prednisone Other / unclassified
Subject Vincristine Small molecule
Subject procarbazine Small molecule
Background Erythropoietin Beta Protein / enzyme biologic

Indications